Dynamics of vaccine uptake in developing country markets

13
CENTER FOR VACCINE INNOVATION AND ACCESS PATH/Gabe Bienczycki Dynamics of vaccine uptake in developing country markets: Achieving impact through successful partnership-a case study with JE vaccines Debbie Atherly PhD, Global Head Policy, Access, & IntroducOon October 26, 2016 DCVMN Annual General MeeOng Buenos Aires, ArgenOna

Transcript of Dynamics of vaccine uptake in developing country markets

CENTER FOR VACC INE I NNOVAT ION AND ACCE S S

PATH/GabeBienczycki

Dynamicsofvaccineuptakeindevelopingcountrymarkets:Achievingimpactthroughsuccessfulpartnership-acasestudywithJEvaccinesDebbieAtherlyPhD,GlobalHeadPolicy,Access,&IntroducOonOctober26,2016

DCVMNAnnualGeneralMeeOngBuenosAires,ArgenOna

CENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESS 2

Workinmorethan70countries.150millionpeoplereachedeachyearonaverage.PATHsnapshot

6billionvaccinevialmonitorsensuringthatvaccinesarepotentwhengiven

6.3millionpeoplereachedwithriceforOfiedwithcriOcalmicronutrients

6.2millionlivessavedwithPATH-pioneeredapproachestomalariacontrol

Weharnessour

entrepreneurialinsight,

scienOficandpublic

healthexperOse,and

passionforhealth

equity…

…tosavethelives

ofwomenandchildren.

CENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESS 3

PATH’sCenterforVaccineInnovaOonandAccess(CVIA)CVIA’sprimaryobjecOveistoacceleratethedevelopmentandintroducOonoflifesavingvaccinesforopOmalpublichealthimpactintheworld’slowestresourcesebngs.Wefocusonvaccinesthatprotectwomenandchildrenfromtheleadingcausesofdiseaseanddeath.

DISEASEAREAS

RespiratoryInfecConsandMaternalImmunizaConpneumococcus•meningococcus•groupBstreptococcus•B.pertussis•influenzavirus•respiratorysyncyOalvirus

EntericandDiarrhealDiseasesrotavirus•enterotoxigenicEscherichiacoli•Shigellassp.•poliovirus

MalariaPlasmodiumfalciparum•Plasmodiumvivax

ZoonoCc,Emerging,andSexuallyTransmiLedInfecConshumanpapillomavirus•JapaneseencephaliOsvirus•denguevirus•yellowfevervirus•outbreaks

CENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESS 4

RESEARCH/DESIGN DEVELOP/VALIDATE APPROVE/RECOMMEND INTRODUCE/OPTIMIZE SCALE-UP/APPLY

•  IdenOfypotenOalvaccineleadsandapproaches

•  ConductiniOalcandidateevaluaOons

•  AddresscountryneedsandprioriOesinproductdevelopment

•  Assessproofofconcept/efficacyinlow-resourcesebngs

•  Generateevidenceforregulatoryreviewandapproval

•  Supportqualitymanufacturingandadequatesupply

•  FacilitateWorldHeathOrganizaOonprequalificaOonandregulatoryapprovalatnaOonallevel

•  Enableevidence-baseddecisionmakingforpublicfinancingandglobalandnaOonalpolicies

•  Supportcountriesonplanning,preparaOon,andintroducOon

•  Capturelearningsfromearlyadopters

•  Ensuresustainablesupply

•  Facilitatewide-scaleuse•  Measureimpact

OurworkspanstheenOrevaccinedevelopmentanddeliveryspectrum

PATH/AaronJoelSantosPATH/MaghewDakinPATH/WillBoase

JapaneseencephaliOsvaccineimpact:AchievingsuccessthroughcollaboraOon

CENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESS 6

JapaneseencephaliOs(JE):AbriefintroducOon

•  JE:mosquito-borneflavivirus;closelyrelatedtodengueandWestNileviruses.

•  LeadingviralcauseofencephaliOsinAsia.

•  Nearly3billionpeopleliveinJE-endemicregions.

•  Childrenandruralpoorsufferthegreatestdiseaseburden.

SolomonT,DungNM,KneenR,GainsboroughM,VaughnDW,KhanhVT.JapaneseencephaliOs.JNeurolNeurosurgPsychiatry.2000Apr;68(4):405-15.

CENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESS 7

CENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESS 8

OurPartnershipwithChengduInsOtuteofBiologicalProducts(CDIBP)•  PartneredonpivotalclinicaltrialstoestablishvaccinesafetyandimmunogencityoutsideofChina

•  ProvidedtechnicalandfinancialsupporttopursueWHOprequalificaOonandmeetrigorousinternaOonalstandardsofquality,safety,andefficacy

•  Assistedinthedesignandfinancingofanewmanufacturingfacilitytoensurehigh-quality,adequate,stablevaccinesupply,whilescalingupproducOonforinternaOonalexport

•  ProvideconOnuedtechnicalandmanufacturingsupporttoadvancevaccineavailabilityandmaintaingoodmanufacturingpracOcestandards

•  Establishedalow,public-sectorvaccinepriceforJE-endemiccountriesthroughourcollaboraOveagreement

•  MonitorJEvaccinesupplytomeetcountrydemand

CENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESS 9

HistoricMoment:JEVaccineWHOPrequalificaOon

CENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESS 10

OtherKeyWins•  A180percentincreaseofCDIBP’sJEvaccineannualproducOon

capacityasresultofanewlyconstructed,GMP-compliantfacility

•  CDIBPcanproduce70milliondosesperyearonaverage,versusthe25milliondosesperyearproducedintheolder,recently-reOredfacility

•  WithinmonthsofWHOPQ,GaviopenedafundingwindowtosupportJEvaccinaConcatch-upcampaignsforchildrenlessthan15yearsofage

•  From2003–2017,anesCmated308millionchildrenoutsideofChinawillbevaccinatedbyCDIBP’svaccine

•  ThroughrecentnegoOaOonsofafairpublichealthpricethatreflectsactualvaccineproducOoncostatCDIBP,weincreasedthelikelihoodofvaccineuptakebyallcountrieswithahighJEburden,notjustGavicountries.ItalsoensuredsustainablevaccineproducOonunOl2033.CDIBP’sJEvaccineremainsoneofthemostcosteffecCvevaccinesonthemarket.

CENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESS 11

KeyMilestonesinJEControlandPrevenOon

2006FirstWHOJEpositionpaperpublished,whichrecommendedreplacingolder,moreexpensivevaccineswithnewgenerationJEvaccines,giventheiradvantageoussafetyprofileandaffordability.

2012Newmanufacturingfacilitycomplete;dosecapacityraisedfrom25Mto70M.

2013WHO“Prequalification”statusobtainedforCD-JEV,whichmeansasafe,effectivevaccineismorewidelyaffordableandaccessible.

2015WHOJEpositionpaperupdated:StronglyendorsesintegratingvaccineintoallnationalimmunizationscheduleswhereJEisrecognizedasapublichealthpriority.

2006India

2007NepalThailand

2008DPRK

2002SouthKoreaSriLanka

2015LaosCambodia

2016Nepal

2017MyanmarVietnamIndonesiaPhilippines

2018Bangladesh

2014Gaviapplicationsopen,whichprovidesfinancingforCD-JEVintroductionforlowandlower-middleincomecountries.

CountryintroductionsofCD-JEV

1988China Vaccinedevelopmentandmanufacturing

PartneracCviCesCountryvaccineintroducCon/expansion

CENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESS 12

China|1988

DPRK|2008

SouthKorea|2002Nepal|2007

JEvaccina=onexpanded2016

MyanmarExpectedintroduc=on2017

BangladeshExpectedintroduc=on2018India|2006

ConOnuestoexpand

SriLanka|2002

Thailand|2007

PhilippinesExpectedintroduc=on2017

IndonesiaExpectedintroduc=on2017

VietnamExpectedexpansion2017

Laos|2015

Cambodia|2016

Country-financedintroducOonofCD-JEVfollowedbyGavi-supportedexpansion

CountriesthathaveintroducedCD-JEV

AnOcipatedGavi-supportedJEvaccineintroducOonorprogramexpansion

Note:YearscorrespondtoyearthatCD-JEVwasincorporatedintochildhoodvaccinaOonprograms

CENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESSCENTERFORVACCINEINNOVATIONANDACCESS 13

Thankyou!QuesOons?